ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 19 November 2026 NSE & BSE filings, as they land
ALFA News Straight from the exchange filing
Partnership

Indegene Joins Indo-UK Life Science Corridor as First Industry Partner

Indegene Limited (NSE: INDGN) has been appointed as the inaugural industry partner for the Indo-UK Life Science Corridor, a strategic initiative by C-CAMP and Imperial College London. The collaboration aims to bridge research, entrepreneurship, and industrial expertise between India and the UK to solve shared global health challenges.

Detailed view of a scientist operating a microscope in a laboratory setting. Stock photo illustrating Indegene's partnership story.
Photo: Tima Miroshnichenko / Pexels
Key numbers
Market Cap ₹15,779.7 CrHealthcare Services
P/E Ratio (TTM) 38.38xSector: 56.76x
Revenue Growth 39.55%Year-on-Year (Q2)
RSI 63.64Daily

Key highlights

  • Indegene is the first industry partner in the Corridor supported by the Imperial Global India initiative
  • Collaboration focuses on co-developing entrepreneurship programs and talent exchange between India and the UK
  • Core focus areas include antimicrobial resistance, digital health, brain science, and mental health
  • The partnership was announced at the Bengaluru Tech Summit 2026 during a joint C-CAMP-Imperial roundtable
  • Indegene reported operating revenue of ₹1,122.3 crore for the quarter ended September 30, 2026

Bridging Research and Industry Across Borders

Indegenes entry as the first industry partner in the Indo-UK Life Science Corridor marks a strategic shift towards accelerating translation pathways for deep-science innovations. By collaborating with C-CAMP and Imperial College London, the company will support two-way knowledge sharing and evidence-based problem solving on priority health challenges. Indegene brings significant scale to the initiative, having already established a track record of serving the worlds top 20 biopharmaceutical companies.

This partnership leverages Indegenes AI-native operating model to refine industry challenges and support startup exchanges, ensuring that promising healthcare technologies from both India and the UK have a clear path to commercial scalability.

Strategic Tie-ups and Domain Focus

  • Initial focus domains include antimicrobial resistance, diagnostics, digital health, and agritech
  • The partnership facilitates startup exchanges and ecosystem immersion programs for emerging life science ventures
  • Oct 2025: Strategic partnership with Verified Market Research for global conjunctivitis allergy market insights
  • Jul 2025: Long-term partnership with FAST India to advance the Indian biotechnology ecosystem
  • May 2025: Collaboration with the Indian School of Public Policy to drive health policy research

Connecting Science and Talent

The next decade of life sciences innovation will be defined by how well we connect science, talent, and industry across borders. This Corridor brings together the strengths of India and the UK, giving promising ideas a clearer path from discovery to real-world impact.

— Dr. Saurabh Jain, Vice President - Global Delivery Centers, CSR, and Advocacy, Indegene

Financial Performance and Sector Outlook

From a financial perspective, Indegene enters this partnership following a strong Q2 FY27 performance where operating revenue reached ₹1,122.3 crore, a 39.55% increase over the same period last year. The companys valuation metrics show a P/E TTM of 38.38, compared to the broader sector P/E of 56.76, while its Momentum Score remains elevated at 67.51. Institutional backing has strengthened, with institutional holdings rising to 28.22% during the latest quarter.

Management remains focused on margin expansion, targeting a return to 19% EBITDA margins by the end of FY27. This corridor involvement aligns with previous strategic moves to digitize clinical operations and expand the deal pipeline.

Indegene · share price, past month
Earlier announcements by Indegene
DateAnnouncementAmount
30 Oct 2025Strategic partnership with Verified Market Research (VMR) to access decision-grade insights on the Global Conjunctivitis Allergy MarketSource: leadiq.com–
19 Sep 2025Strategic partnership with Datavant to integrate data enrichment into the NEXT Patient Recruitment platform for rare and complex disease clinical trialsSource: insights.indegene.com–
03 Jul 2025Strategic long-term partnership with Foundation for Advancing Science and Technology (FAST) India to advance research and scale the Indian biotechnology ecosystemSource: fast-india.org–
06 May 2025Strategic collaboration with Indian School of Public Policy (ISPP) to co-create the Centre for Advancing Universal Health Coverage and drive health policy researchSource: NSE filing–
09 Jan 2025Strategic partnership with CliniOps, Inc. to accelerate clinical trial operations and digital transformation in patient recruitment and data servicesSource: insights.indegene.com–

What to watch next

  • Target recovery of quarterly EBITDA margin to 19%+ by Q4 FY27
  • Approval and filing of Q3 FY27 financial results on or before Feb 14, 2027
  • Projected 15% plus annual revenue growth in the BioPharm unit for FY27

“Welcoming Indegene as the first industry partner of the Indo-UK Life Sciences Innovation Corridor is an important moment for this partnership. When we launched the initiative with C-CAMP earlier this year, we wanted to create a platform where research, talent and industry could come together to accelerate new technologies and solve shared global challenges.”

— Amanda Wolthuizen, Vice-President (Strategy), Imperial College London

“Global health challenges cannot be solved in isolation. This understanding was central to our vision for the Indo-UK Life Science Corridor, which connects the complementary innovation ecosystems of Imperial College London and C-CAMP to enable cross border problem-solving.”

— Dr. Taslimarif Saiyed, CEO, C-CAMP
Indegene · financial snapshot
Share price₹654.95
Market capitalisation₹15,779.70 Cr
Revenue (annual)₹3,510.50 Cr
Net profit (annual)₹401.10 Cr
Revenue (latest quarter)₹1,122.30 Cr+5.57% vs previous quarter
Net profit (latest quarter)₹112.30 Cr-3.36% vs previous quarter
P/E (TTM)38.38×Sector 56.76×
Promoter holding0%0.00% QoQ
FII holding12.4%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

Exchange filing by Indegene Limited announcing its appointment as the first industry partner of the Indo-UK Life Science Corridor. Market figures from a third-party data provider.

Read the filing ↗
Every Indegene announcement on ALFA FilingsSee filings →

More in Partnerships

All →